Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489809 | 1.00 | JAK2 (0.35) | JAK2NTRK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489382 | 0.95 | JAK2 (0.36) | JAK2NTRK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489877 | 0.90 | JAK2 (0.36) | JAK2PIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL31489342 | 0.90 | JAK2 (0.36) | JAK2PIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL31489510 | 0.86 | PIK3CD (0.38) | JAK2NTRK1PIK3CDPIK3CGPDK2 | |
| SCHEMBL31489223 | 0.86 | PIK3CG (0.39) | NTRK1PIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL31489507 | 0.86 | PIK3CG (0.39) | NTRK1PIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL31489400 | 0.86 | PIK3CD (0.34) | JAK2NTRK1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489460 | 0.85 | PIK3CD (0.36) | JAK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489337 | 0.85 | JAK2 (0.32) | JAK2NTRK1PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |